Taltz Dosage/Direction for Use

Taltz is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Taltz is indicated.
Posology: Plaque psoriasis in adults: The recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg (one injection) at Weeks 2, 4, 6, 8, 10, and 12, then maintenance dosing of 80 mg (one injection) every 4 weeks (Q4W).
Paediatric plaque psoriasis (age 6 years and above): Efficacy and safety data is not available in children below the age of 6 years (see Pharmacology: Pharmacodynamics under Actions).
The recommended dose given by subcutaneous injection in children is based on the following weight categories: TALTZ is administered by subcutaneous injection every 4 weeks (Q4W). The recommended dose in pediatric patients from 6 to less than 18 years of age with moderate-to-severe plaque psoriasis is based on the following weight categories. (See Table 12.)

Click on icon to see table/diagram/image

Taltz is not recommended for use in children with a body weight below 25 kg. Paediatric body weights must be recorded and regularly re-checked prior to dosing.
Pre-filled pen: Ixekizumab doses of 40 mg must be prepared and administered by a qualified healthcare professional using the commercial Taltz 80 mg/1 ml prefilled syringe.
Use the Taltz 80 mg pre-filled pen only in those children that require a dose of 80 mg and do not require dose preparation.
Pre-filled syringe: For children prescribed 80 mg, Taltz can be used directly from the prefilled syringe.
For instructions on preparation of Taltz 40 mg, see Special precautions for disposal and other handling under Cautions for Usage. Doses less than 80 mg must be prepared by a healthcare professional.
Psoriatic arthritis: The recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks thereafter. For psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis, the recommended dosing regimen is the same as for plaque psoriasis.
Axial spondyloarthritis (radiographic and non-radiographic): The recommended dose is 160 mg (two 80 mg injections) by subcutaneous injection at Week 0, followed by 80 mg every 4 weeks (see Pharmacology: Pharmacodynamics under Actions for further information).
For all indications (plaque psoriasis in adults and children, psoriatic arthritis, axial spondyloarthritis) consideration should be given to discontinuing treatment in patients who have shown no response after 16 to 20 weeks of treatment. Some patients with initially partial response may subsequently improve with continued treatment beyond 20 weeks.
Elderly (≥65 years): No dose adjustment is required (see Pharmacology: Pharmacokinetics under Actions).
There is limited information in subjects aged ≥75 years.
Renal or hepatic impairment: Taltz has not been studied in these patient populations. No dose recommendations can be made.
Paediatric plaque psoriasis (below a body weight of 25 kg and below the age of 6 years): There is no relevant use of Taltz in children below a body weight of 25 kg and below the age of 6 years in the treatment of moderate to severe plaque psoriasis.
Paediatric psoriatic arthritis: The safety and efficacy of Taltz in children and adolescents aged 2 to less than 18 years in the treatment of psoriatic arthritis (a category of juvenile idiopathic arthritis) have not yet been established. No data are available. There is no relevant use of Taltz in children below 2 years for the indication of psoriatic arthritis.
Method of administration: Subcutaneous use.
Taltz is for subcutaneous injection. Injection sites may be alternated. If possible, areas of the skin that show psoriasis should be avoided as injection sites. The solution/the pen or syringe must not be shaken.
After proper training in subcutaneous injection technique, patients may self-inject Taltz if a healthcare professional determines that it is appropriate. However, the physician should ensure appropriate follow-up of patients. Comprehensive instructions for administration are given in the package leaflet and the user manual.
Pre-filled syringe: Doses less than 80 mg which require dose preparation should only be administered by a healthcare professional.